The immunocytochemical expression of VE-1 (BRAF V600E-related) antibody identifies the aggressive variants of papillary thyroid carcinoma on liquid-based cytology

Patrizia Straccia; Chiara Brunelli; Esther D Rossi; Paola Lanza; Maurizio Martini; Teresa Musarra; Celestino Pio Lombardi; Alfredo Pontecorvi; Guido Fadda

doi:10.1111/cyt.12690

The immunocytochemical expression of VE-1 (BRAF V600E-related) antibody identifies the aggressive variants of papillary thyroid carcinoma on liquid-based cytology

Patrizia Straccia^*, Chiara Brunelli, Esther D Rossi, Paola Lanza, Maurizio Martini, Teresa Musarra, Celestino Pio Lombardi, Alfredo Pontecorvi, Guido Fadda

^*Corresponding author

Research output: Contribution to journal › Article

4 Citations (Scopus)

Abstract

The recently introduced monoclonal V600E antibody (clone VE1) is likely to be an alternative strategy for detecting this mutation in thyroid lesions. Although VE1 immunostaining and molecular methods used to assess papillary thyroid carcinoma in surgical specimens are in good agreement, evaluation of VE1 in cytology and cell block samples is rarely performed, and its diagnostic value in cytology has not been well established. In this study, we sought to determine if VE1 is suitable for FNA and cell block method.

Original language	English
Pages (from-to)	1-23
Number of pages	23
Journal	Cytopathology
Issue number	Marzo
DOIs	https://doi.org/10.1111/cyt.12690
Publication status	Published - 2019

All Science Journal Classification (ASJC) codes

Pathology and Forensic Medicine
Histology

Keywords

BRAFV600E antibody (clone VE1)
PTC
Thyroid nodules
cell block
fine needle aspiration

Access to Document

10.1111/cyt.12690

Cite this

@article{906b5ae341cf4104b9a3859bb53d1cc6,

title = "The immunocytochemical expression of VE-1 (BRAF V600E-related) antibody identifies the aggressive variants of papillary thyroid carcinoma on liquid-based cytology",

abstract = "The recently introduced monoclonal V600E antibody (clone VE1) is likely to be an alternative strategy for detecting this mutation in thyroid lesions. Although VE1 immunostaining and molecular methods used to assess papillary thyroid carcinoma in surgical specimens are in good agreement, evaluation of VE1 in cytology and cell block samples is rarely performed, and its diagnostic value in cytology has not been well established. In this study, we sought to determine if VE1 is suitable for FNA and cell block method.",

keywords = "BRAFV600E antibody (clone VE1), PTC, Thyroid nodules, cell block, fine needle aspiration, BRAFV600E antibody (clone VE1), PTC, Thyroid nodules, cell block, fine needle aspiration",

author = "Patrizia Straccia and Chiara Brunelli and Rossi, {Esther D} and Paola Lanza and Maurizio Martini and Teresa Musarra and Lombardi, {Celestino Pio} and Alfredo Pontecorvi and Guido Fadda",

year = "2019",

doi = "10.1111/cyt.12690",

language = "English",

pages = "1--23",

journal = "Cytopathology",

issn = "0956-5507",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "Marzo",

}

TY - JOUR

T1 - The immunocytochemical expression of VE-1 (BRAF V600E-related) antibody identifies the aggressive variants of papillary thyroid carcinoma on liquid-based cytology

AU - Straccia, Patrizia

AU - Brunelli, Chiara

AU - Rossi, Esther D

AU - Lanza, Paola

AU - Martini, Maurizio

AU - Musarra, Teresa

AU - Lombardi, Celestino Pio

AU - Pontecorvi, Alfredo

AU - Fadda, Guido

PY - 2019

Y1 - 2019

N2 - The recently introduced monoclonal V600E antibody (clone VE1) is likely to be an alternative strategy for detecting this mutation in thyroid lesions. Although VE1 immunostaining and molecular methods used to assess papillary thyroid carcinoma in surgical specimens are in good agreement, evaluation of VE1 in cytology and cell block samples is rarely performed, and its diagnostic value in cytology has not been well established. In this study, we sought to determine if VE1 is suitable for FNA and cell block method.

AB - The recently introduced monoclonal V600E antibody (clone VE1) is likely to be an alternative strategy for detecting this mutation in thyroid lesions. Although VE1 immunostaining and molecular methods used to assess papillary thyroid carcinoma in surgical specimens are in good agreement, evaluation of VE1 in cytology and cell block samples is rarely performed, and its diagnostic value in cytology has not been well established. In this study, we sought to determine if VE1 is suitable for FNA and cell block method.

KW - BRAFV600E antibody (clone VE1)

KW - PTC

KW - Thyroid nodules

KW - cell block

KW - fine needle aspiration

KW - BRAFV600E antibody (clone VE1)

KW - PTC

KW - Thyroid nodules

KW - cell block

KW - fine needle aspiration

UR - https://publicatt.unicatt.it/handle/10807/132558

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85064700315&origin=inward

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85064700315&origin=inward

U2 - 10.1111/cyt.12690

DO - 10.1111/cyt.12690

M3 - Article

SN - 0956-5507

SP - 1

EP - 23

JO - Cytopathology

JF - Cytopathology

IS - Marzo

ER -

The immunocytochemical expression of VE-1 (BRAF V600E-related) antibody identifies the aggressive variants of papillary thyroid carcinoma on liquid-based cytology

Abstract

All Science Journal Classification (ASJC) codes

Keywords

Access to Document

Other files and links

Fingerprint

Cite this